A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

May 21, 2026 updated by: GlaxoSmithKline

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

The study consists of three parts:

  • Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+).
  • Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different dose ratios of belantamab mafodotin in combination with Unconjugated belantamab antibody (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+).
  • Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the unconjugated belantamab antibody, either alone or in combination with belantamab mafodotin alongside the standard of care (SoC) pomalidomide-dexamethasone backbone. The study will focus on patients with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

152

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Argentina
      • Ciudadela, Argentina, B1702
        • Completed
        • GSK Investigational Site
      • San Juan Bautista, Argentina, B1888AAE
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Maria Julieta Dalmaroni
      • Viedma, Argentina, R8500ACE
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Rubén Kowalyszyn
  • Australia
    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hang Quach
        • Contact:
        • Contact:
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Completed
        • GSK Investigational Site
  • Brazil
      • Joinville, Brazil, 89201-260
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marcelo Pitombeira Lacerda
      • Salvador, Brazil, 41253-190
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Edvan de Queiroz Crusoe
      • São Paulo, Brazil, 04537-080
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Vania Hungria
  • Japan
      • Aomori, Japan, 030-8553
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tomoaki Akagi
      • Chiba, Japan, 277-8577
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Junichiro Yuda
        • Contact:
        • Contact:
      • Kanagawa, Japan, 221-0855
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tomonori Nakazato
      • Osaka, Japan, 545-8586
        • Completed
        • GSK Investigational Site
      • Tokyo, Japan, 105-8471
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kazuhito Suzuki
        • Contact:
        • Contact:
      • Yamagata, Japan, 990-9585
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Satoshi Ito
        • Contact:
        • Contact:
  • Poland
      • Gdansk, Poland, 80-214
        • Withdrawn
        • GSK Investigational Site
      • Lublin, Poland, 20-081
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marek Hus
  • South Korea
      • Seoul, South Korea, 138-736
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Dok Hyun Yoon
        • Contact:
        • Contact:
      • Seoul, South Korea, 137-701
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • chang-ki min
  • Taiwan
      • Changhua, Taiwan, 500
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hsuan-Yu Lin
      • Kaohsiung City, Taiwan, 807
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Shih-Feng Cho
      • Taipei, Taiwan, 100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • SHANG YI Huang
  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye), 34010
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • SINEM BOZDAG
      • Kayseri, Turkey (Türkiye), 38039
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Neslihan Mandaci sanli
  • United Kingdom
      • Leicester, United Kingdom, LE1 5WW
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Linda Barton
      • Oxford, United Kingdom, OX3 7LE
        • Completed
        • GSK Investigational Site
      • Plymouth, United Kingdom, PL6 8DH
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hannah Hunter
        • Contact:
        • Contact:
  • United States
    • Michigan
      • Grand Rapids, Michigan, United States, 49546
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Andrew Sochacki
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Eben Lichtman
        • Contact:
        • Contact:
    • Tennessee
      • Chattanooga, Tennessee, United States, 37404
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jesus Berdeja
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jesus Berdeja

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants at the time of signing the Informed Consent Form (ICF) are at least 18 years old or are of the legal age of consent in the jurisdiction in which the study is taking place.
  • Participants who have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the international myeloma working group (IMWG) and have progressed on or following the last line of treatment Part 1 and Part 2: Participants who have received at least 3 prior lines of anti-myeloma treatments, , including lenalidomide, a proteasome inhibitor, and an anti-CD38 mAb either in combination or separately.
  • Part 3: Have received at least 1 prior line of treatment anti-myeloma treatments, including lenalidomide. Prior anti-CD38-containing regimen is not mandated, however no more than 70% of participants recruited may be anti-CD38 naïve
  • Participants with a history of Autologous stem cell transplant (ASCT) are eligible for study participation provided the following eligibility criteria are met:
  • Transplant was greater than (>)100 days prior to screening.
  • No active bacterial, viral, or fungal infection(s) present
  • Eastern cooperative oncology group-performance status (ECOG-PS) of 0 to 2.
  • Measurable disease defined as at least ONE of the following:
  • Serum M-protein concentration greater than (>=) 0.5 gram (g)/ deciliter (dL) (>=5 gram/liter [g/L])
  • Urine M-protein excretion >=200 milligram(mg)/24 hours (>=0.2 g/24 hours)
  • Serum free light chain (FLC) assay: involved FLC level >=10 mg/dL (>=100 milligrams per liter [mg/L]) and an abnormal serum FLC ratio (less than [<]0.26 or >1.65)
  • Have adequate organ system function as defined by the laboratory assessments
  • All prior treatment-related toxicities (defined by National Cancer Institute-Common Toxicity Criteria for Adverse Events [NCI-CTCAE], v5.0, 2017) must be Grade <=1 at the time of screening except for alopecia (any grade), neuropathy (Grade <=2), or endocrinopathy managed with replacement therapy (any grade).
  • Participants or legally authorized representative (LAR) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
  • Is NOT a Participant of child-bearing potential (POCBP) or
  • Is a POCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency during the intervention period and for 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
  • Part 3: Due to pomalidomide being a thalidomide analogue with a risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution programme, POCBP will be eligible if they commit either to abstain continuously from heterosexual sexual intercourse or use two methods of reliable birth control (one method that is highly effective plus an additional barrier method), beginning at least 4 weeks prior to initiating treatment with pomalidomide, during therapy, during dose interruptions and continuing for at least 4 weeks following discontinuation of pomalidomide treatment. Thereafter, POCBP must use one contraceptive method that is highly effective (with a failure rate of less than (<)1 percentage (%) per year) for a further 3 months (total 4 months).
  • The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention
  • All POCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period

Exclusion Criteria:

  • Diagnosis of primary Amyloid Light chain (AL) Amyloidosis, active Polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome, primary plasma cell leukemia.
  • Part 3: Active or history of venous or arterial thromboembolism within the past 3 months. Contraindications to or unwilling to undergo protocol-required anti-thrombotic prophylaxis
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures.
  • Participant is exhibiting signs of meningeal or central nervous system involvement with MM.
  • Current corneal epithelial disease except nonconfluent Superficial punctate keratitis (SPK).
  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Presence of malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the Principal investigator (PI) and GlaxoSmithKline (GSK) Medical Director, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).Participants on active surveillance or hormone treatment for non-metastatic prostate cancer are not excluded. Participants on hormone therapy for non-metastatic breast cancer are not excluded
  • Evidence of cardiovascular risk including any of the following:
  • Evidence of current clinically significant untreated arrhythmias, including, but not limited to, clinically significant Electrocardiogram (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree Atrioventricular (AV) block.
  • Part 1 dose escalation and Part 2 only: QT interval corrected using Fridericia's formula (QTcF) interval >480 millisecond(msec) (QT interval corrected for heart rate according to Fridericia's formula), and/or hypokalemia, and/or family history of long QT syndrome.
  • Part 1 dose expansion and Part 3: Not applicable.
  • History of MI, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting or bypass grafting, all within three months of screening.
  • Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
  • Uncontrolled hypertension
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Unconjugated belantamab antibody / belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other Monoclonal antibodies (mAbs).
  • Active infection requiring antibiotic, antiviral, or antifungal treatment.
  • For serology of HBsAg+ at screen or within 3 months prior to first dose Japan only: must test hepatitis B e-antigen (HBeAg) and antibody to hepatitis B e-antigen (HBeAb.) Eligibility verification should be evaluated and agreed with a hepatologist (after they record the approval in the patient medical record).
  • Known Human immunodeficiency virus (HIV) infection, unless the participant can meet specific criteria.
  • Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction.
  • Participants with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) will be excluded unless specific criteria can be met.
  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible.
  • Part 1: Refractory to belantamab mafodotin (confirmed PD as per IMWG criteria while on belantamab mafodotin therapy or within 60 days of completing that treatment). Prior belantamab mafodotin is allowed if it was discontinued due to toxicity which subsequently resolved Note: Prior treatment with other anti-BCMA directed agents is allowed. Provided there is at least 6-month washout after the last dose of prior anti-BCMA therapy.
  • Part 2: Prior belantamab mafodotin therapy is not allowed. Prior treatment with other anti-BCMA directed agents is allowed provided there is at least a 6-month washout after the last doseof prior anti-BCMA therapy to start of study therapy.
  • Prior radiotherapy within 2 weeks of start of study therapy.
  • Plasmapheresis within 7 days prior to the first dose of study drug.
  • Prior allogeneic transplant is prohibited.
  • Participants who have received prior Chimeric Antigen Receptor T-cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
  • Any major surgery (other than bone-stabilizing surgery) within 2 weeks of first dose or has not recovered fully from surgery.
  • Prior treatment with a mAb within 30 days of receiving the first dose of study drugs, or treatment with an investigational agent or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is longer.
  • Part 1: Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including Granulocyte colony stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GMCSF), recombinant erythropoietin) or any thrombopoietin receptor agonists within 2 weeks before the first dose of study drug.
  • Part 3:Prior Unconjugated belantamab antibody, belantamab mafodotin, and pomalidomide therapy. are not allowed. Prior treatment with other anti- B-cell maturation antigen (BCMA) directed agents is allowed provided there is at least 6-month washout after the last dose of prior anti-BCMA therapy.
  • Participants must not receive live/live attenuated vaccines within 30 days prior to first dose of study treatment or whilst receiving Unconjugated belantamab antibody for at least 70 days following last study treatment.
  • Known, current drug or alcohol abuse.
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective Independent Review Board (IRB) approval (by chair or designee) is allowing exception to this criterion for a specific participant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part 1: Dose escalation and expansion of the unconjugated belantamab antibody monotherapy
Unconjugated belantamab antibody will be administered in participants with RRMM until progressive disease (PD)
Drug: Unconjugated belantamab antibody
Unconjugated belantamab antibody will be administered.
Other Names:
  • GSK2857914
Experimental: Part 2:Unconjugated belantamab antibody and belantamab mafodotin-given separately dose range finding
Participants with RRMM will receive unconjugated belantamab antibody and belantamab mafodotin
Drug: Unconjugated belantamab antibody and belantamab mafodotin
Unconjugated belantamab antibody and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.
Other Names:
  • GSK2857914 and GSK2857916
Experimental: Part 3: Unconjugated belantamab +/- belantamab mafodotin +pomalidomide/dexamethasone in 2L+ RRMM
Participants with second line (2L+) RRMM will receive Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin.
Drug: Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin
Unconjugated belantamab antibody and belantamab mafodotin in combination with pomalidomide-dexamethasone and Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone will be administered.
Experimental: Part 1b:Optional belantamab mafodotin
Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.
Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.
Other Names:
  • GSK2857916

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part 1, 2 and 3: Number of Participants with any Adverse Event
Time Frame: Up to 52 months
Up to 52 months
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
Time Frame: Cycle 1 (Each cycle is of 28 days)
Cycle 1 (Each cycle is of 28 days)
Part 2: Overall Response Rate (ORR)
Time Frame: Up to 52 months
Up to 52 months
Part 1, 2and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign Parameters
Time Frame: Up to 52 months
Up to 52 months
Part 1, 2 and 3: Number of Participants with severity of ocular events by the Keratopathy Visual Acuity (KVA) scale
Time Frame: Up to 52 months
Up to 52 months
Part 3: Very Good Partial Response and better rate (VGPR+)
Time Frame: Up to 52 months
VGPR+ is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, complete response, stringent complete response)
Up to 52 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part 1: Observed Plasma Concentration of belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 1: Area Under the Curve (AUC) of belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 1: Maximum Concentration (Cmax) of belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 1: Number of Participants with Anti-Drug Antibodies (ADA) against belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 1: Titers of ADA against belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 1: Overall Response Rate (ORR)
Time Frame: Up to 52 months
Up to 52 months
Part 2: Duration of Response (DoR)
Time Frame: Up to 52 months
Up to 52 months
Part 2: Observed Plasma Concentration of Total belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 2: Area Under the Curve (AUC) of Total belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 1: Maximum Concentration (Cmax) of Total belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 2: Area Under the Curve (AUC) of belantamab mafodotin (ADC)
Time Frame: Up to 52 months
Up to 52 months
Part 2: Observed Plasma Concentration of Cys-Monomethyl Auristatin-F (Cys-mcMMAF)
Time Frame: Up to 52 months
Up to 52 months
Part 2: Area Under the Curve (AUC) of Cys-mcMMAF
Time Frame: Up to 52 months
Up to 52 months
Part 2: Observed Plasma Concentration of belantamab mafodotin (ADC)
Time Frame: Up to 52 months
Up to 52 months
Part 2: Maximum Concentration (Cmax) of belantamab mafodotin (ADC)
Time Frame: Up to 52 months
Up to 52 months
Part 2: Maximum Concentration (Cmax) of Cys-mcMMAF
Time Frame: Up to 52 months
Up to 52 months
Part 2: Number of Participants with ADAs against Unconjugated belantamab antibody and belantamab mafodotin
Time Frame: Up to 52 months
Up to 52 months
Part 2: Titers of ADAs against Unconjugated belantamab antibody and belantamab mafodotin
Time Frame: Up to 52 months
Up to 52 months
Part 3: Minimal residual disease (MRD) negativity rate in participants achieving at least VGPR
Time Frame: Up to 52 months
MRD negativity rate is defined as the percentage of participants who achieve MRD negative status at 10-5 sensitivity threshold assessed by next generation sequencing at least once during the time of confirmed VGPR+ response per International myeloma working group (IMWG) criteria.
Up to 52 months
Part 3: Overall Response Rate (ORR)
Time Frame: Up to 52 months
Up to 52 months
Part 3: Duration Of Response (DoR)
Time Frame: Up to 52 months
Up to 52 months
Part 3: Observed Plasma Concentration of Total belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 3: Area Under the Curve (AUC) of Total belantamab
Time Frame: Up to 52 months
Up to 52 months
Part 3: Observed Plasma Concentration of belantamab mafodotin (ADC)
Time Frame: Up to 52 months
Up to 52 months
Part 3: Area Under the Curve (AUC) of belantamab mafodotin (ADC)
Time Frame: Up to 52 months
Up to 52 months
Part 3: Maximum Concentration (Cmax) of belantamab mafodotin (ADC)
Time Frame: Up to 52 months
Up to 52 months
Part 3: Observed Plasma Concentration of Cys-Monomethyl Auristatin-F (Cys-mcMMAF)
Time Frame: Up to 52 months
Up to 52 months
Part 3: Area Under the Curve (AUC) of Cys-mcMMAF
Time Frame: Up to 52 months
Up to 52 months
Part 3: Maximum Concentration (Cmax) of Cys-mcMMAF
Time Frame: Up to 52 months
Up to 52 months
Part 3: Number of Participants with ADAs against Unconjugated belantamab antibody and belantamab mafodotin
Time Frame: Up to 52 months
Up to 52 months
Part 3: Titers of ADAs against Unconjugated belantamab antibody and belantamab mafodotin
Time Frame: Up to 52 months
Up to 52 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2023

Primary Completion (Estimated)

December 3, 2029

Study Completion (Estimated)

December 3, 2029

Study Registration Dates

First Submitted

January 27, 2023

First Submitted That Met QC Criteria

January 27, 2023

First Posted (Actual)

February 6, 2023

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 218670
  • 2022-501941-63 (EudraCT Number: CTIS)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD Sharing Time Frame

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD Sharing Access Criteria

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Belantamab mafodotin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe